624 related articles for article (PubMed ID: 34122422)
21. Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non-Small-Cell Lung Cancer.
Naidoo J; Nishino M; Patel SP; Shankar B; Rekhtman N; Illei P; Camus P
Clin Lung Cancer; 2020 Sep; 21(5):e435-e444. PubMed ID: 32576443
[TBL] [Abstract][Full Text] [Related]
22. Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis.
Wang H; Guo X; Zhou J; Li Y; Duan L; Si X; Zhang L; Liu X; Wang M; Shi J; Zhang L
Thorac Cancer; 2020 Jan; 11(1):191-197. PubMed ID: 31762218
[TBL] [Abstract][Full Text] [Related]
23. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
[TBL] [Abstract][Full Text] [Related]
24. Recurrent and atypical immune checkpoint inhibitor-induced pneumonitis.
Jeon WJ; Nguyen J; Castillo DR; Park K; Brothers J; Nguyen A; Mirshahidi H
J Oncol Pharm Pract; 2023 Jul; 29(5):1264-1267. PubMed ID: 36648206
[TBL] [Abstract][Full Text] [Related]
25. Clinical Outcomes of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Non-small Cell Lung Cancer and Preexisting Interstitial Lung Diseases: A Systematic Review and Meta-analysis.
Zhang M; Fan Y; Nie L; Wang G; Sun K; Cheng Y
Chest; 2022 Jun; 161(6):1675-1686. PubMed ID: 35026298
[TBL] [Abstract][Full Text] [Related]
26. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
Chu X; Zhao J; Zhou J; Zhou F; Jiang T; Jiang S; Sun X; You X; Wu F; Ren S; Zhou C; Su C
Lung Cancer; 2020 Dec; 150():76-82. PubMed ID: 33080551
[TBL] [Abstract][Full Text] [Related]
27. The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients.
Zhai X; Zhang J; Tian Y; Li J; Jing W; Guo H; Zhu H
Cancer Biol Med; 2020 Aug; 17(3):599-611. PubMed ID: 32944393
[TBL] [Abstract][Full Text] [Related]
28. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
29. Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and Beyond.
Reuss JE; Suresh K; Naidoo J
Curr Oncol Rep; 2020 May; 22(6):56. PubMed ID: 32415399
[TBL] [Abstract][Full Text] [Related]
30. Immune-related organizing pneumonitis in non-small cell lung cancer receiving PD-1 inhibitor treatment: A case report and literature review.
Yin B; Xiao J; Li J; Liu X; Wang J
J Cancer Res Ther; 2020; 16(7):1555-1559. PubMed ID: 33565499
[TBL] [Abstract][Full Text] [Related]
31. Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma.
Apostolidis J; Sayyed A; Darweesh M; Kaloyannidis P; Al Hashmi H
J Immunol Res; 2020; 2020():9350272. PubMed ID: 33178841
[TBL] [Abstract][Full Text] [Related]
32. Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors.
Hu X; Wang L; Shang B; Wang J; Sun J; Liang B; Su L; You W; Jiang S
Front Immunol; 2023; 14():1094414. PubMed ID: 36949956
[TBL] [Abstract][Full Text] [Related]
33. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.
Wu Z; Man S; Sun R; Li Z; Wu Y; Zuo D
Int Immunopharmacol; 2020 Aug; 85():106613. PubMed ID: 32450531
[TBL] [Abstract][Full Text] [Related]
34. Overview of checkpoint inhibitor pneumonitis: incidence and associated risk factors.
Shibata Y; Murakami S; Kato T
Expert Opin Drug Saf; 2021 May; 20(5):537-547. PubMed ID: 33650443
[No Abstract] [Full Text] [Related]
35. Pneumonitis associated with immune checkpoint inhibitors among patients with non-small cell lung cancer.
Shannon VR
Curr Opin Pulm Med; 2020 Jul; 26(4):326-340. PubMed ID: 32452900
[TBL] [Abstract][Full Text] [Related]
36. Immune-mediated adverse effects of immune-checkpoint inhibitors and their management in cancer.
Jin KT; Wang SB; Ying XJ; Lan HR; Lv JQ; Zhang LH; Motallebnezhad M; Mou XZ
Immunol Lett; 2020 May; 221():61-71. PubMed ID: 32097671
[TBL] [Abstract][Full Text] [Related]
37. Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials.
Shi Y; Duan J; Guan Q; Xue P; Zheng Y
Int Immunopharmacol; 2020 Jul; 84():106452. PubMed ID: 32339922
[TBL] [Abstract][Full Text] [Related]
38. Immune Checkpoint Inhibitor-Related Pneumonitis.
Gomatou G; Tzilas V; Kotteas E; Syrigos K; Bouros D
Respiration; 2020; 99(11):932-942. PubMed ID: 33260191
[TBL] [Abstract][Full Text] [Related]
39. The Many Faces of Immune Checkpoint Inhibitor-Associated Pneumonitis: 4 Case Reports.
Mojsak D; Dębczyński M; Kuklińska B; Moniuszko-Malinowska A; Mróz RM
Am J Case Rep; 2022 Jun; 23():e936420. PubMed ID: 35648729
[TBL] [Abstract][Full Text] [Related]
40. A nomogram model for predicting the risk of checkpoint inhibitor-related pneumonitis for patients with advanced non-small-cell lung cancer.
Zhang Y; Zhang L; Cao S; Wang Y; Ling X; Zhou Y; Zhong H
Cancer Med; 2023 Aug; 12(15):15998-16010. PubMed ID: 37409360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]